Teonanacatl

Borderline Personality Disorder

University of ChicagoSmall moleculePhase 2Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

4 Active assets in the Borderline Personality Disorder cohort.

Asset / Sponsor	Phase	Rating
Selegiline Mood and Anxiety Research, Inc	Phase 3	BB
CITALOPRAM Columbia Northwest Pharmaceuticals	Phase 2	B
LITHIUM, ELEMENTAL Columbia Northwest Pharmaceuticals	Phase 2	B
Midazolam Joshua Rosenblat	Phase 2	CCC
Escitalopram University of Chicago	Phase 2	CCC

View all 9 →

Same molecule, other indications

Teonanacatl is also rated in:

depressive disorderActive

BB

Indicative · Phase 2

68 / 100

major depressive disorderActive

BB

Indicative · Phase 3

65 / 100

hematopoietic and lymphoid system neoplasmActive

BB

Indicative · Phase 2

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.